158 related articles for article (PubMed ID: 33581330)
1. Exploring the genetic mechanisms underlying amoxicillin-clavulanate resistance in waterborne Escherichia coli.
Singh NS; Singhal N; Kumar M; Virdi JS
Infect Genet Evol; 2021 Jun; 90():104767. PubMed ID: 33581330
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor-resistant TEM- and OXA-1-producing Escherichia coli isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates.
Oteo J; González-López JJ; Ortega A; Quintero-Zárate JN; Bou G; Cercenado E; Conejo MC; Martínez-Martínez L; Navarro F; Oliver A; Bartolomé RM; Campos J;
Antimicrob Agents Chemother; 2014 Jul; 58(7):3874-81. PubMed ID: 24777096
[TBL] [Abstract][Full Text] [Related]
3. β-lactamases produced by amoxicillin-clavulanate-resistant enterobacteria isolated in Buenos Aires, Argentina: a new blaTEM gene.
Di Conza JA; Badaracco A; Ayala J; Rodríguez C; Famiglietti A; Gutkind GO
Rev Argent Microbiol; 2014; 46(3):210-7. PubMed ID: 25444130
[TBL] [Abstract][Full Text] [Related]
4. Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli.
Rodríguez-Villodres Á; Gutiérrez Linares A; Gálvez-Benitez L; Pachón J; Lepe JA; Smani Y
Microbiol Spectr; 2021 Oct; 9(2):e0080121. PubMed ID: 34668721
[TBL] [Abstract][Full Text] [Related]
5. Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli.
Rodríguez-Villodres Á; Gil-Marqués ML; Álvarez-Marín R; Bonnin RA; Pachón-Ibáñez ME; Aguilar-Guisado M; Naas T; Aznar J; Pachón J; Lepe JA; Smani Y
J Antimicrob Chemother; 2020 Jan; 75(1):77-85. PubMed ID: 31613964
[TBL] [Abstract][Full Text] [Related]
6. Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States.
Kaye KS; Gold HS; Schwaber MJ; Venkataraman L; Qi Y; De Girolami PC; Samore MH; Anderson G; Rasheed JK; Tenover FC
Antimicrob Agents Chemother; 2004 May; 48(5):1520-5. PubMed ID: 15105100
[TBL] [Abstract][Full Text] [Related]
7. Resistance to piperacillin/tazobactam in Escherichia coli resulting from extensive IS26-associated gene amplification of blaTEM-1.
Hansen KH; Andreasen MR; Pedersen MS; Westh H; Jelsbak L; Schønning K
J Antimicrob Chemother; 2019 Nov; 74(11):3179-3183. PubMed ID: 31411684
[TBL] [Abstract][Full Text] [Related]
8. Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli.
Schechter LM; Creely DP; Garner CD; Shortridge D; Nguyen H; Chen L; Hanson BM; Sodergren E; Weinstock GM; Dunne WM; van Belkum A; Leopold SR
mBio; 2018 Apr; 9(2):. PubMed ID: 29691340
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Inhibitor-Resistant TEM β-Lactamases and Mechanisms of Fluoroquinolone Resistance in Escherichia coli Isolates.
Ríos E; López MC; Rodríguez-Avial I; Pena I; Picazo JJ
Microb Drug Resist; 2015 Oct; 21(5):512-5. PubMed ID: 25945693
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
11. β-Lactamases in amoxicillin-clavulanate-resistant Escherichia coli strains isolated from a Chinese tertiary hospital.
Ding J; Ma X; Chen Z; Feng K
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):532-3. PubMed ID: 23726651
[TBL] [Abstract][Full Text] [Related]
12. Modified Antibiotic Adjuvant Ratios Can Slow and Steer the Evolution of Resistance: Co-amoxiclav as a Case Study.
Allen RC; Brown SP
mBio; 2019 Sep; 10(5):. PubMed ID: 31530673
[TBL] [Abstract][Full Text] [Related]
13. Spanish multicenter study of the epidemiology and mechanisms of amoxicillin-clavulanate resistance in Escherichia coli.
Ortega A; Oteo J; Aranzamendi-Zaldumbide M; Bartolomé RM; Bou G; Cercenado E; Conejo MC; González-López JJ; Marín M; Martínez-Martínez L; Merino M; Navarro F; Oliver A; Pascual A; Rivera A; Rodríguez-Baño J; Weber I; Aracil B; Campos J
Antimicrob Agents Chemother; 2012 Jul; 56(7):3576-81. PubMed ID: 22491692
[TBL] [Abstract][Full Text] [Related]
14. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological and clinical complexity of amoxicillin-clavulanate-resistant Escherichia coli.
Rodríguez-Baño J; Oteo J; Ortega A; Villar M; Conejo MC; Bou G; Aranzamendi-Zaldumbide M; Cercenado E; Gurguí M; Martínez-Martínez L; Merino M; Rivera A; Oliver A; Weber I; Pascual A; Bartolomé RM; Gónzalez-López JJ; Campos J
J Clin Microbiol; 2013 Jul; 51(7):2414-7. PubMed ID: 23637303
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
17. Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli.
Suzuki Y; Sato T; Fukushima Y; Nakajima C; Suzuki Y; Takahashi S; Yokota SI
Int J Antimicrob Agents; 2020 Apr; 55(4):105919. PubMed ID: 32062000
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
[TBL] [Abstract][Full Text] [Related]
19. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
Vanjak D; Muller-Serieys C; Picard B; Bergogne-Berezin E; Lambert-Zechovsky N
Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):972-8. PubMed ID: 8654448
[TBL] [Abstract][Full Text] [Related]
20. beta-Lactam resistance phenotype determination in Escherichia coli isolates from University Malaya Medical Centre.
Wong JS; Mohd Azri ZA; Subramaniam G; Ho SE; Palasubramaniam S; Navaratnam P
Malays J Pathol; 2003 Dec; 25(2):113-9. PubMed ID: 16196367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
